Ten post jest także dostępny w języku: polski
Paulina Romaniszyn was appointed as Country Head and General Manager in the Polish branch of Stada. The new Head will use the experience she has gained previously and take care of the implementation of the adopted development strategy.
Experience of Romaniszyn in pharmaceutical companies
Paulina Romaniszyn became the new head of the Polish branch of the Stada. As Country Head and General Manager of the Stada she will supervise a wide range of products in many therapeutic categories. These include biosimilar drugs, prescription drugs, as well as OTC products and dietary supplements. The new Head is expected to draw on extensive experience in the hospital and procurement industry, including biosimilars such as filgrastim and pegfilgrastim, as well as in the generic and OTC retail segments.
Romaniszyn has over twenty years of experience in working for pharmaceutical companies. Before moving to Stada, Paulina Romaniszyn held a similar position at Accord Healthcare, where she was responsible for development as country manager. She has proven experience in building marketing and sales strategies, including implementation and running multifunctional teams.
Stada development – recent acquisitions and future ambitions
Over the past year, Stada has significantly strengthened its position in the pharmaceutical market, especially in the OTC segment. In November 2019, the company announced the acquisition of the Czech company Walmark from the Mid Europa Partners fund (we have written more about it here). In December 2019, Stada announced the acquisition of the pharmaceutical division of Biopharma, one of the leading manufacturers in Ukraine. In late 2019, Stada also acquired from Takeda 20 products in Eastern Europe. Furthermore, in February 2020 we wrote about the acquisition of several key OTC brands from GSK.
According to the information provided by the company in a statement of 14 September 2020, recently the Polish branch of Stada in the OTC product segment has almost doubled its market share in Poland. An important element of building its position was the previously described acquisitions. Stada is planning further development in Poland, especially in the generic segment, especially in the area of painkillers. Stada is also cooperating with Alvotech, Insud mAbxience and Xbrane Biopharma in the development of biosimilar therapies. It intends to become a key player in this segment in the future.